Synlogic Inc. (SYBX)
1.40
-0.01 (-0.71%)
At close: Jan 15, 2025, 3:58 PM
1.46
3.95%
After-hours Jan 15, 2025, 03:59 PM EST
undefined% (undefined)
| Bid | 1.26 |
| Market Cap | 16.43M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.5 |
| PE Ratio (ttm) | -0.94 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 1.49 |
| Volume | 11,515 |
| Avg. Volume (20D) | 35,222 |
| Open | 1.37 |
| Previous Close | 1.41 |
| Day's Range | 1.36 - 1.44 |
| 52-Week Range | 1.22 - 3.73 |
| Beta | undefined |
About SYBX
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 30, 2015
Employees 6
Stock Exchange NASDAQ
Ticker Symbol SYBX
Website https://www.synlogictx.com
Analyst Forecast
According to 3 analyst ratings, the average rating for SYBX stock is "Hold." The 12-month stock price forecast is $1, which is a decrease of -28.80% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
11 months ago ·
Source
-48.7%
Synlogic shares are trading lower after the compan...
Unlock content with
Pro Subscription
11 months ago ·
Source
-1.99%
Synlogic shares are trading lower after the company announced it will discontinue Synpheny-3, cease operations and reduce its workforce by more than 90%.
